Gleevec at 25: The origin, impact and legacy of the first targeted cancer therapy

Short summary

In this episode, NPR’s Short Wave marks the 25th anniversary of Gleevec’s FDA approval and traces how a targeted cancer drug began a new era in oncology. The story weaves together the science behind the Philadelphia chromosome, the pivotal role of Dr. Brian Drucker in pursuing targeted therapy, the patient-driven momentum that sped clinical trials, and the regulatory victory that reshaped cancer care. It also follows Mel Mann, whose life was saved by early therapies and who went on to complete remarkable feats, illustrating the human impact of this medical breakthrough.

• imatinib as the first targeted cancer drug
• Philadelphia chromosome and the BCR-ABL fusion as a growth driver
• Dr. Brian Drucker’s shift to Oregon Health and Science University and the rapid trials
• patient advocacy and rapid FDA approval
• ongoing legacy with generations of targeted therapies and affordability progress

Overview and context

The podcast commemorates the 25th anniversary of Gleevec (imatinib), the first targeted cancer medicine, and explains how its development shifted cancer treatment from broad chemotherapy to precision strategies guided by genetic insights. The episode situates the story within a broader landscape of collaboration among researchers, clinicians, government funders, and industry, highlighting how understanding the genetic underpinnings of cancer can translate into life-saving therapies.

The origin story: from hypothesis to therapeutic breakthrough

At the core of the origin is the idea of turning off a cancer growth switch rather than indiscriminately killing cells. Chronic myeloid leukemia (CML) is linked to a genetic abnormality known as the Philadelphia chromosome, which creates a fused gene producing an enzyme that drives uncontrolled white blood cell proliferation. Oncologist Brian Drucker, facing skepticism in traditional cancer drug development, moved across the country to pursue this targeted approach. In Oregon, Drucker tested multiple compounds from a drug company that would become Novartis, with one of them—Gleevec—showing promise in lab models. Drucker also became a bridge to patients who were eager to enroll in trials and pushed for rapid progress.

Clinical trials and data that changed medicine

The early trials were distinctive in focusing on a single cancer type rather than aggregating different cancers. By 1999, data showed remarkable responses: the abnormal enzyme could be switched off, white blood cell counts normalized, and survival signals began to defy expectations. A biostatistician, Insa Gothman, led the analysis of survival curves and witnessed results that looked almost too good to be true, only to confirm that they were accurate. The clinical teams demonstrated that a small molecule could selectively inhibit the disease mechanism, catalyzing a new era of precision oncology.

From data to regulatory action: a record-setting approval

With compelling early results and a growing global patient interest, Novartis and its partners advanced the data package to the FDA. The approval on May 10, 2001 became the fastest drug approval at the time, taking 72 days. The story emphasizes a chain of collaboration: foundational genetic discoveries funded by the National Cancer Institute, risk-taking by the pharmaceutical company, and patient voices that accelerated access and momentum. The Philadelphia chromosome discovery, a milestone in cancer genetics, was rooted in NIH-supported research, underscoring the long arc from basic science to clinical impact.

Impact, legacy and ongoing story

Gleevec did not merely treat CML; it established a new paradigm for cancer therapy. Since then, more than 100 targeted cancer drugs have entered the market, with improvements in overall survival and quality of life for many patients. The narrative also highlights Mel Mann, diagnosed in 1995 with a grim prognosis who later benefited from Gleevec, enabling him to complete personal milestones and pursue marathon running. It also touches on broader outcomes, including late-generation inhibitors that expanded the drug’s reach to other tumors and the economics of cancer medicines, noting that while Gleevec was expensive at launch, it eventually became generic and more affordable.

People behind the science

The episode honors Dr. Brian Drucker for his persistent pursuit of targeted therapy and acknowledges the patient community, researchers, and clinicians who contributed to the rapid development and deployment of Gleevec. It also recognizes Insa Gothman for the critical role of biostatistics in interpreting survival data and the Novartis team that drove the program forward. The collective effort is presented as a landmark example of what scientific collaboration and patient partnership can achieve in medicine.

Looking forward

The story closes by framing Gleevec as the turning point that catalyzed precision oncology. The ongoing work in targeted therapies, diagnostics, and affordability continues to evolve, expanding treatment options and illustrating how genetic insights can continue to transform patient outcomes across a range of cancers.